Prostatic carcinoma with positive lymph nodes – the case for primary hormone therapy

[1]  J. Manola,et al.  IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL , 1999 .

[2]  D. Kirk,et al.  RE: IMMEDIATE VERSUS DEFERRED TREATMENT FOR ADVANCED PROSTATE CANCER: INITIAL RESULTS OF THE MEDICAL RESEARCH COUNCIL TRIAL (EDITORIAL COMMENT) , 1998 .

[3]  W. Sause,et al.  Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. , 1998, International journal of radiation oncology, biology, physics.

[4]  S. Hancock.  Node-positive prostatic cancer: taps or a call to arms? , 1998, International journal of radiation oncology, biology, physics.

[5]  J. Earle,et al.  Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. , 1998, International journal of radiation oncology, biology, physics.

[6]  W. Schneider,et al.  Radikale Prostatektomie beim lymphogen metastasierten Prostatakarzinom , 1997 .

[7]  B. Lowe,et al.  Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. , 1997, The Journal of urology.

[8]  J. Cadeddu,et al.  Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. , 1997, Urology.

[9]  R. Parker,et al.  Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate. , 1997, American journal of clinical oncology.

[10]  P. Troncoso,et al.  The significance of DNA‐ploidy and S‐phase fraction in node‐positive (stage D1) prostate cancer treated with androgen ablation , 1997, The Prostate.

[11]  O. Dalesio,et al.  Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials. , 1997, Urology.

[12]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Schmeller,et al.  Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. , 1997, British journal of urology.

[14]  Z. Petrovich,et al.  Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate. , 1994, Urology.

[15]  F. Schröder,et al.  Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. , 1994, The Journal of urology.

[16]  S. Fosså,et al.  Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. , 1993, The Journal of urology.

[17]  E. Bergstralh,et al.  Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy , 1993, Cancer.

[18]  J. Oesterling,et al.  Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. , 1992, The Journal of urology.

[19]  H. Zincke,et al.  Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) , 1991, The Journal of urology.

[20]  P. Walsh,et al.  Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. , 1990, The Journal of urology.

[21]  P. Scardino,et al.  Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.

[22]  L. Kavoussi,et al.  Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. , 1988, The Journal of urology.

[23]  K. Matsumoto,et al.  Growth-stimulatory effect of androgen-induced autocrine growth factor(s) secreted from Shionogi carcinoma 115 cells on androgen-unresponsive cancer cells in a paracrine mechanism. , 1988, Cancer research.

[24]  E. Kramolowsky.  The value of testosterone deprivation in stage D1 carcinoma of the prostate. , 1988, The Journal of urology.

[25]  W. Taylor,et al.  Treatment options for patients with stage D1 (T0-3,N1-2,M0) adenocarcinoma of prostate. , 1988, Urology.

[26]  T. Therneau,et al.  Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. , 1988, Mayo Clinic proceedings.

[27]  F. Schröder,et al.  Early orchiectomy for patients with stage D1 prostatic carcinoma. , 1985, The Journal of urology.

[28]  P. Brawn.  The dedifferentiation of prostate carcinoma , 1983, Cancer.

[29]  W. Whitmore,et al.  Prostatic adenocarcinoma: relationship of grade and local extent to the pattern of metastases. , 1977, The Journal of urology.

[30]  K. Kurth,et al.  Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease Prostate-specific antigen as predictor of quality of life , 2004, Urological Research.

[31]  D. Paulson,et al.  Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? , 2004, World Journal of Urology.

[32]  N. Schmeller.  ADJUVANTE THERAPIE BEI LYMPHKNOTENPOSITIVEM PROSTATAKARZINOM , 1998 .

[33]  M. Mihatsch,et al.  Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. , 1997, European urology.

[34]  M. Wirth,et al.  Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. , 1995, European urology.

[35]  H. Zincke.  Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C or D1 adenocarcinoma of the prostate: possible beneficial effect of adjuvant treatment. , 1988, NCI monographs : a publication of the National Cancer Institute.